Rhinomaris, 0.05% spray 15 ml

Pharmacotherapeutic group
Antagonist – vasoconstrictor (alpha-adrenomimetic).
ATX code: R01AA07

Pharmacokinetics
Pharmacokinetics
Almost not absorbed by local administration. Plasma concentrations are so low as to be undetectable by modern analytical methods.

Pharmacological properties
Rhinomaris is a drug for intranasal application.

Xylometazoline has alpha-adrenomimetic action: it causes nasal mucosa blood vessels narrowing thus eliminating nasopharyngeal mucosa edema and hyperemia. Facilitates nasal breathing in rhinitis. In therapeutic concentrations it does not irritate nasal mucosa, does not cause hyperemia. The action starts a few minutes after application and lasts for 12 hours.

Sterilized sea water, contained in Rhinomaris, helps maintain normal physiologic condition of nasal mucosa, thinning of mucus and normalization of its production in bocalytic cells of nasal cavity mucosa.

Micronutrients improve the function of the atrial fibrillation epithelium, reducing adverse local reactions such as irritation and/or dryness of the nasopharyngeal mucosa.

Indications

acute respiratory diseases with symptoms of rhinitis (runny nose);
allergic rhinitis (hay fever);
sinusitis;
eustachitis;
otitis media (to reduce swelling of the nasopharyngeal mucosa);
preparing the patient for diagnostic manipulations in the nasal passages.

Pharmacological effect

Pharmacotherapeutic group
Anticongestant – vasoconstrictor (alpha-adrenergic agonist).
ATX CODE: R01AA07

Pharmacokinetics
When applied topically, it is practically not absorbed; plasma concentrations are so small that they cannot be determined by modern analytical methods.

Pharmacological properties
Rinomaris is a drug for intranasal use.

Xylometazoline has an alpha-adrenomimetic effect: it causes a constriction of the blood vessels of the nasal mucosa, thus eliminating swelling and hyperemia of the nasopharyngeal mucosa. Facilitates nasal breathing during rhinitis. In therapeutic concentrations it does not irritate the mucous membranes and does not cause hyperemia. The effect begins a few minutes after application and lasts for 12 hours.

Sterilized sea water, which is part of the drug Rinomaris, helps maintain the normal physiological state of the nasal mucosa, thins mucus and normalizes its production in the goblet cells of the nasal mucosa.

Microelements improve the function of the ciliated epithelium, which reduces adverse local reactions such as irritation and/or dryness of the nasopharyngeal mucosa.

Special instructions

Before use, it is necessary to clean the nasal passages.
Rinomaris® should not be used for a long time, for example, for chronic rhinitis.

Impact on the ability to drive vehicles and operate machinery
Xylometazoline in doses higher than recommended may affect the ability to operate vehicles or equipment.

Active ingredient

Xylometazoline

Composition

Composition in mg per 1 ml of the drug: 0.05%

Active ingredient

Xylometazoline hydrochloride 0.500

Excipients

Adriatic Sea water 251,000

Potassium dihydrogen phosphate 0.502

Purified water up to 1 ml

Pregnancy

During pregnancy and lactation, the drug should be used only after a thorough assessment of the risk-benefit ratio for the mother and fetus; recommended doses should not be exceeded.

Contraindications

Arterial hypertension, tachycardia, severe atherosclerosis, glaucoma, atrophic rhinitis, thyrotoxicosis, surgical interventions on the meninges (history), children under 2 years of age (for a 0.05% solution), hypersensitivity to the components of the drug.

Precautions
Use with caution for diabetes mellitus, angina pectoris (CHD).

Side Effects

With frequent and/or prolonged use – irritation and/or dryness of the nasopharyngeal mucosa, burning, tingling, sneezing, hypersecretion, swelling of the nasal mucosa.
Palpitations, tachycardia, arrhythmias, increased blood pressure, headache, vomiting, insomnia, blurred vision; with long-term use in high doses – depression.

Overdose

Symptoms: increased side effects.

Treatment: symptomatic therapy.

Storage conditions

The drug should be stored out of the reach of children at a temperature not exceeding 25°C.

Shelf life

3 years. Do not use after the expiration date stated on the package.

Manufacturer

JADRAN-GALENSKI LABORATORY j.s., Croatia